Sabra Healthcare Reit Stock Buy Hold or Sell Recommendation
| SBRA Stock | USD 16.42 0.54 3.40% |
Given the investment horizon of 90 days and your above-average risk tolerance, our recommendation regarding Sabra Healthcare REIT is 'Hold'. Macroaxis provides Sabra Healthcare buy-hold-or-sell recommendation only in the context of selected investment horizon and investor attitude towards risk assumed by holding SBRA positions.
Check out Sabra Healthcare Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. In addition, we conduct extensive research on individual companies such as Sabra and provide practical buy, sell, or hold advice based on investors' investing horizon and their risk tolerance towards Sabra Healthcare REIT. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in metropolitan statistical area.
Sabra |
Execute Sabra Healthcare Buy or Sell Advice
The Sabra recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Sabra Healthcare REIT. Macroaxis does not own or have any residual interests in Sabra Healthcare REIT or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Sabra Healthcare's advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Hold
Market Performance | Very Weak | Details | |
Volatility | Very steady | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Fairly Valued | Details | |
Odds Of Distress | Low | Details | |
Economic Sensitivity | Follows the market closely | Details | |
Investor Sentiment | Interested | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Sabra Healthcare Trading Alerts and Improvement Suggestions
| Sabra Healthcare generated a negative expected return over the last 90 days | |
| Sabra Healthcare REIT currently holds 1.76 B in liabilities with Debt to Equity (D/E) ratio of 0.76, which is about average as compared to similar companies. Sabra Healthcare REIT has a current ratio of 0.76, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Sabra Healthcare's use of debt, we should always consider it together with its cash and equity. | |
| Over 99.0% of Sabra Healthcare shares are owned by institutional investors | |
| Latest headline from gurufocus.com: Sabra Health Care REIT Inc Reports Strong Fourth Quarter 2024 Results |
Sabra Healthcare Returns Distribution Density
The distribution of Sabra Healthcare's historical returns is an attempt to chart the uncertainty of Sabra Healthcare's future price movements. The chart of the probability distribution of Sabra Healthcare daily returns describes the distribution of returns around its average expected value. We use Sabra Healthcare REIT price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Sabra Healthcare returns is essential to provide solid investment advice for Sabra Healthcare.
| Mean Return | -0.11 | Value At Risk | -3.05 | Potential Upside | 2.59 | Standard Deviation | 1.64 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Sabra Healthcare historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Sabra Stock Institutional Investors
| Shares | Hhg Plc | 2024-12-31 | 3.5 M | Dimensional Fund Advisors, Inc. | 2024-12-31 | 3.3 M | Wellington Management Company Llp | 2024-12-31 | 3.2 M | Norges Bank | 2024-12-31 | 2.8 M | Nuveen Asset Management, Llc | 2024-09-30 | 2.6 M | Amvescap Plc. | 2024-12-31 | 2.6 M | Duff & Phelps Inv Mgmt Co (il) | 2024-12-31 | 2.5 M | Goldman Sachs Group Inc | 2024-12-31 | 2.5 M | Systematic Financial Management Lp | 2024-12-31 | 2.4 M | Blackrock Inc | 2024-12-31 | 37 M | Vanguard Group Inc | 2024-12-31 | 35 M |
Sabra Healthcare Cash Flow Accounts
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Change In Cash | 16.4M | 50.4M | (62.0M) | (7.2M) | 19.6M | 20.6M | |
| Free Cash Flow | 249.3M | 322.8M | 315.7M | 300.6M | 310.5M | 181.2M | |
| Depreciation | 176.7M | 179.0M | 187.8M | 183.1M | 169.6M | 121.6M | |
| Other Non Cash Items | 1.6M | 32.2M | 217.8M | 98.5M | 5.2M | 5.0M | |
| Capital Expenditures | 93.4M | 252.5M | 105.6M | 33.6M | 146.7M | 5.2M | |
| End Period Cash Flow | 65.5M | 115.9M | 53.9M | 46.7M | 66.3M | 88.6M | |
| Change To Inventory | 6.4M | (8.2M) | 6.4M | 11.1M | 12.7M | 13.4M | |
| Dividends Paid | 278.3M | 262.9M | 277.2M | 277.4M | 280.2M | 209.6M | |
| Net Income | 138.4M | (113.3M) | (77.6M) | 13.8M | 126.7M | 133.0M | |
| Investments | 3.7M | (287.1M) | (161.5M) | 103.1M | (109.0M) | (103.6M) | |
| Net Borrowings | (624M) | (3.9M) | (15.7M) | 122.8M | 110.5M | 116.0M | |
| Change To Netincome | 165.4M | 38.5M | 233.8M | 212.0M | 243.8M | 256.0M |
Sabra Healthcare Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Sabra Healthcare or Diversified REITs sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Sabra Healthcare's price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Sabra stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.12 | |
β | Beta against Dow Jones | 0.58 | |
σ | Overall volatility | 1.68 | |
Ir | Information ratio | -0.07 |
Sabra Healthcare Volatility Alert
Sabra Healthcare REIT exhibits very low volatility with skewness of -0.2 and kurtosis of 0.13. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Sabra Healthcare's stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Sabra Healthcare's stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Sabra Healthcare Fundamentals Vs Peers
Comparing Sabra Healthcare's fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Sabra Healthcare's direct or indirect competition across all of the common fundamentals between Sabra Healthcare and the related equities. This way, we can detect undervalued stocks with similar characteristics as Sabra Healthcare or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Sabra Healthcare's fundamental indicators could also be used in its relative valuation, which is a method of valuing Sabra Healthcare by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Sabra Healthcare to competition |
| Fundamentals | Sabra Healthcare | Peer Average |
| Return On Equity | 0.0457 | -0.31 |
| Return On Asset | 0.03 | -0.14 |
| Profit Margin | 0.18 % | (1.27) % |
| Operating Margin | 0.37 % | (5.51) % |
| Current Valuation | 6.16 B | 16.62 B |
| Shares Outstanding | 237.91 M | 571.82 M |
| Shares Owned By Insiders | 1.31 % | 10.09 % |
| Shares Owned By Institutions | 98.69 % | 39.21 % |
| Number Of Shares Shorted | 17.72 M | 4.71 M |
| Price To Earning | 67.37 X | 28.72 X |
| Price To Book | 1.38 X | 9.51 X |
| Price To Sales | 5.56 X | 11.42 X |
| Revenue | 703.24 M | 9.43 B |
| Gross Profit | 476.12 M | 27.38 B |
| EBITDA | 412.61 M | 3.9 B |
| Net Income | 126.71 M | 570.98 M |
| Cash And Equivalents | 49.05 M | 2.7 B |
| Cash Per Share | 0.21 X | 5.01 X |
| Total Debt | 1.76 B | 5.32 B |
| Debt To Equity | 0.76 % | 48.70 % |
| Current Ratio | 0.78 X | 2.16 X |
| Book Value Per Share | 11.54 X | 1.93 K |
| Cash Flow From Operations | 310.54 M | 971.22 M |
| Short Ratio | 10.50 X | 4.00 X |
| Earnings Per Share | 0.54 X | 3.12 X |
| Price To Earnings To Growth | 3.15 X | 4.89 X |
| Target Price | 19.58 | |
| Number Of Employees | 50 | 18.84 K |
| Beta | 1.24 | -0.15 |
| Market Capitalization | 3.91 B | 19.03 B |
| Total Asset | 5.3 B | 29.47 B |
| Retained Earnings | (1.87 B) | 9.33 B |
| Working Capital | 355.11 M | 1.48 B |
Note: Acquisition by Cusack Catherine of 1500 shares of Sabra Healthcare at 15.92 subject to Rule 16b-3 [view details]
Sabra Healthcare Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Sabra . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Sabra Healthcare Buy or Sell Advice
When is the right time to buy or sell Sabra Healthcare REIT? Buying financial instruments such as Sabra Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Sabra Healthcare in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Global Macro ETFs Thematic Idea Now
Global Macro ETFs
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The Global Macro ETFs theme has 27 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Global Macro ETFs Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Sabra Healthcare Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.
Is Diversified REITs space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Sabra Healthcare. If investors know Sabra will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Sabra Healthcare listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth 1.827 | Dividend Share 1.2 | Earnings Share 0.54 | Revenue Per Share | Quarterly Revenue Growth 0.125 |
The market value of Sabra Healthcare REIT is measured differently than its book value, which is the value of Sabra that is recorded on the company's balance sheet. Investors also form their own opinion of Sabra Healthcare's value that differs from its market value or its book value, called intrinsic value, which is Sabra Healthcare's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Sabra Healthcare's market value can be influenced by many factors that don't directly affect Sabra Healthcare's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Sabra Healthcare's value and its price as these two are different measures arrived at by different means. Investors typically determine if Sabra Healthcare is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Sabra Healthcare's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.